JP2011518176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518176A5 JP2011518176A5 JP2011505202A JP2011505202A JP2011518176A5 JP 2011518176 A5 JP2011518176 A5 JP 2011518176A5 JP 2011505202 A JP2011505202 A JP 2011505202A JP 2011505202 A JP2011505202 A JP 2011505202A JP 2011518176 A5 JP2011518176 A5 JP 2011518176A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- alkyl
- benzyl
- phenyl
- unbranched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 21
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical class [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 19
- -1 nitrobenzenesulfonyl Chemical group 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000003441 thioacyl group Chemical group 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 0 CC*=*1*(C)=**=C1** Chemical compound CC*=*1*(C)=**=C1** 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- HNJOAIYFUCQZAA-UHFFFAOYSA-N Cc1n[o]c(C)n1 Chemical compound Cc1n[o]c(C)n1 HNJOAIYFUCQZAA-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4538608P | 2008-04-16 | 2008-04-16 | |
| US61/045,386 | 2008-04-16 | ||
| PCT/US2009/040799 WO2009137251A2 (en) | 2008-04-16 | 2009-04-16 | Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014147954A Division JP5892561B2 (ja) | 2008-04-16 | 2014-07-18 | 統合失調症を治療し、薬物渇望を低減するためのシステイン及びシスチンのバイオ同配体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518176A JP2011518176A (ja) | 2011-06-23 |
| JP2011518176A5 true JP2011518176A5 (enExample) | 2014-04-10 |
| JP5658137B2 JP5658137B2 (ja) | 2015-01-21 |
Family
ID=40933521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505202A Expired - Fee Related JP5658137B2 (ja) | 2008-04-16 | 2009-04-16 | 統合失調症又は薬物渇望治療用医薬組成物 |
| JP2014147954A Expired - Fee Related JP5892561B2 (ja) | 2008-04-16 | 2014-07-18 | 統合失調症を治療し、薬物渇望を低減するためのシステイン及びシスチンのバイオ同配体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014147954A Expired - Fee Related JP5892561B2 (ja) | 2008-04-16 | 2014-07-18 | 統合失調症を治療し、薬物渇望を低減するためのシステイン及びシスチンのバイオ同配体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100048587A1 (enExample) |
| EP (1) | EP2265594A2 (enExample) |
| JP (2) | JP5658137B2 (enExample) |
| CA (1) | CA2721433A1 (enExample) |
| WO (1) | WO2009137251A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5658137B2 (ja) * | 2008-04-16 | 2015-01-21 | マーケット ユニバーシティー | 統合失調症又は薬物渇望治療用医薬組成物 |
| EP2515654A4 (en) * | 2009-12-23 | 2013-04-24 | Map Pharmaceuticals Inc | NEW ERGOLINANALOGA |
| JP5978136B2 (ja) * | 2010-03-10 | 2016-08-24 | プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド | プロピオン酸、プロピオン酸エステルおよび関連化合物 |
| EP2723735A4 (en) | 2011-06-23 | 2015-02-18 | Map Pharmaceuticals Inc | NOVEL ANALOGUES OF FLUORO-ERGOLINE |
| AU2012355982A1 (en) | 2011-12-19 | 2014-07-10 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| US8946420B2 (en) | 2011-12-21 | 2015-02-03 | Map Pharmaceuticals, Inc. | Neuromodulatory compounds |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| LT3066089T (lt) | 2013-11-08 | 2020-02-25 | Promentis Pharmaceuticals, Inc. | Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai |
| US9193681B1 (en) | 2014-05-30 | 2015-11-24 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
| EP3305325B1 (en) * | 2015-06-04 | 2025-07-30 | National Center of Neurology and Psychiatry | Mental illness therapeutic agent having il-6 inhibitor as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW343965B (en) * | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
| BR9811486A (pt) * | 1997-07-25 | 2000-09-19 | Nippon Kayaku Kk | Derivados de ciclopentanona, de cetona e de aminocetona b-di-substituìda, e, composições farmacêutica, para o tratamento de distúrbios nervosos centrais e periféricos e para promover a diferenciação de célula nervosa. |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| DE10138578A1 (de) * | 2001-08-06 | 2003-02-27 | Bayer Ag | Heterocyclylarylsulfonamide |
| SE0301653D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| WO2008008380A1 (en) * | 2006-07-12 | 2008-01-17 | Regents Of The University Of Minnesota | Combination therapy for addiction disorders |
| JP5658137B2 (ja) * | 2008-04-16 | 2015-01-21 | マーケット ユニバーシティー | 統合失調症又は薬物渇望治療用医薬組成物 |
-
2009
- 2009-04-16 JP JP2011505202A patent/JP5658137B2/ja not_active Expired - Fee Related
- 2009-04-16 EP EP09743238A patent/EP2265594A2/en not_active Withdrawn
- 2009-04-16 US US12/425,063 patent/US20100048587A1/en not_active Abandoned
- 2009-04-16 WO PCT/US2009/040799 patent/WO2009137251A2/en not_active Ceased
- 2009-04-16 CA CA2721433A patent/CA2721433A1/en not_active Abandoned
-
2014
- 2014-07-18 JP JP2014147954A patent/JP5892561B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2022542291A5 (enExample) | ||
| JP2022512478A5 (enExample) | ||
| JP2013155195A5 (enExample) | ||
| JP2007523881A5 (enExample) | ||
| JP2018505146A5 (enExample) | ||
| JP2009500424A5 (enExample) | ||
| JP2022513223A5 (enExample) | ||
| KR102645633B1 (ko) | 신경학적 장애를 치료하는 방법 | |
| JP2014527070A5 (enExample) | ||
| JP2013545745A5 (enExample) | ||
| JP2013540114A5 (enExample) | ||
| JP2005524648A5 (enExample) | ||
| JP2008528658A5 (enExample) | ||
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2013520405A5 (enExample) | ||
| JP2021073257A5 (enExample) | ||
| BR112019021056B1 (pt) | Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular | |
| JP2019534893A5 (enExample) | ||
| WO2020230780A1 (ja) | Ｒａｓ阻害ペプチド | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| JP2009500045A5 (enExample) | ||
| JP2005501060A (ja) | 硫黄含有有機硝酸化合物の使用法 |